## Opioid Use Disorder in Pregnancy: Pharmacotherapy Management ### Clinical Context This patient has: - Opioid use disorder on stable buprenorphine maintenance - Pregnancy (8 weeks) - Good treatment adherence and negative illicit drug screen - Concern about fetal safety **Key Point:** Untreated opioid use disorder in pregnancy is associated with high rates of relapse, illicit drug use, and poor maternal and fetal outcomes. Maintenance therapy is safer than withdrawal or abstinence. ### Safety of Opioid Agonists in Pregnancy | Agent | Fetal Risk | Neonatal Withdrawal | Maternal Relapse | Recommendation | |-------|-----------|-------------------|------------------|----------------| | **Buprenorphine** | **Low** (Category C) | **Mild–moderate** | Low | **First-line** | | **Methadone** | Low (Category C) | **Severe** | Low | Alternative | | **Heroin/illicit** | **High** (intrauterine growth restriction, prematurity, stillbirth) | Severe | High | **Contraindicated** | | Naltrexone | Unknown; not recommended | — | High | Contraindicated | | Abrupt withdrawal | — | — | Very high | **Contraindicated** (risk of seizures, preterm labor) | ### Evidence for Buprenorphine in Pregnancy **High-Yield:** Buprenorphine is now preferred over methadone in pregnancy because: 1. **Lower neonatal abstinence syndrome (NAS) severity** - Buprenorphine: mild–moderate NAS (shorter duration, less pharmacotherapy needed) - Methadone: severe NAS (prolonged, requires morphine treatment) 2. **Partial agonist profile** → lower fetal exposure at equivalent doses 3. **Better maternal outcomes** - Lower relapse rates - Easier dose adjustment - Can be prescribed in office-based settings 4. **No teratogenic effects** reported in large prospective cohorts - Normal birth weight - Normal developmental outcomes at follow-up 5. **Abrupt withdrawal is dangerous** in pregnancy - Risk of seizures, preterm labor, fetal loss - Maternal stress triggers relapse **Clinical Pearl:** The goal is **maternal stability and prevention of relapse**, not abstinence. A stable, compliant mother on maintenance therapy has better pregnancy outcomes than an abstinent mother who relapses to heroin. ### Management During Pregnancy ```mermaid flowchart TD A[Pregnant woman with OUD]:::outcome --> B{On maintenance therapy?}:::decision B -->|Yes, stable| C[Continue current agent]:::action B -->|No, or unstable| D[Initiate buprenorphine]:::action C --> E[Buprenorphine preferred]:::action D --> E E --> F[Coordinate with OB/GYN]:::action F --> G[Increase fetal monitoring]:::action G --> H[Plan for NAS management at delivery]:::action H --> I[Postpartum: continue maintenance]:::action ``` **Mnemonic:** **BUMP** = **B**uprenorphine **U**se in **M**aternity is **P**referred ### Specific Recommendations for This Patient 1. **Continue buprenorphine 12 mg/day** (no dose change needed if stable) 2. **Coordinate care** with obstetrics and neonatology 3. **Increase fetal monitoring** (ultrasound, NST as indicated) 4. **Plan for neonatal care** - Educate about mild NAS symptoms - Arrange rooming-in and breastfeeding (buprenorphine is safe in breast milk) - Have morphine available if NAS treatment needed (rarely required with buprenorphine) 5. **Postpartum:** Continue maintenance therapy; do NOT discontinue **Warning:** Abrupt discontinuation of buprenorphine in pregnancy is contraindicated — risk of withdrawal-induced seizures, preterm labor, and fetal loss. ### Neonatal Outcomes - Birth weight: normal with buprenorphine - NAS incidence: ~60% (vs. 80–90% with methadone) - NAS severity: mild–moderate (vs. severe with methadone) - Pharmacotherapy for NAS: rarely needed (~10% vs. 50% with methadone) [cite:Harrison 21e Ch 474; ACOG Committee Opinion 2017]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.